MedTrace Logo

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

NCT03661866 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 15000

Last updated 2026-03-20

No results posted yet for this study

Summary

TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

Conditions

Sponsors & Collaborators

  • Target PharmaSolutions, Inc.

    lead INDUSTRY

Principal Investigators

  • Laura Dalfonso · Target RWE

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-21
Primary Completion
2050-12-31
Completion
2050-12-31

Countries

  • United States
  • Canada
  • Germany
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03661866 on ClinicalTrials.gov